Details

Autor(en) / Beteiligte

• Kassin, Michael T
• Varble, Nicole
• Blain, Maxime
• Xu, Sheng
• Turkbey, Evrim B
• Harmon, Stephanie
• Yang, Dong
• Xu, Ziyue
• Roth, Holger
• Xu, Daguang
• Flores, Mona
• Amalou, Amel
• Sun, Kaiyun
• Kadri, Sameer
• Patella, Francesca
• Cariati, Maurizio
• Scarabelli, Alice
• Stellato, Elvira
• Ierardi, Anna Maria
• Carrafiello, Gianpaolo
• An, Peng
• Turkbey, Baris
• Wood, Bradford J

Titel

Generalized chest CT and lab curves throughout the course of COVID-19

Ist Teil von

• Scientific reports, 2021-03, Vol.11 (1), p.6940-6940, Article 6940

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• A better understanding of temporal relationships between chest CT and labs may provide a reference for disease severity over the disease course. Generalized curves of lung opacity volume and density over time can be used as standardized references from well before symptoms develop to over a month after recovery, when residual lung opacities remain. 739 patients with COVID-19 underwent CT and RT-PCR in an outbreak setting between January 21st and April 12th, 2020. 29 of 739 patients had serial exams (121 CTs and 279 laboratory measurements) over 50 ± 16 days, with an average of 4.2 sequential CTs each. Sequential volumes of total lung, overall opacity and opacity subtypes (ground glass opacity [GGO] and consolidation) were extracted using deep learning and manual segmentation. Generalized temporal curves of CT and laboratory measurements were correlated. Lung opacities appeared 3.4 ± 2.2 days prior to symptom onset. Opacity peaked 1 day after symptom onset. GGO onset was earlier and resolved later than consolidation. Lactate dehydrogenase, and C-reactive protein peaked earlier than procalcitonin and leukopenia. The temporal relationships of quantitative CT features and clinical labs have distinctive patterns and peaks in relation to symptom onset, which may inform early clinical course in patients with mild COVID-19 pneumonia, or may shed light upon chronic lung effects or mechanisms of medical countermeasures in clinical trials.